BillionToOne, Inc. operates a high-complexity CLIA-certified laboratory to provide molecular diagnostic testing services. The company's flagship product, UNITY Complete, is a non-invasive prenatal screening test that assesses fetal risk for aneuploidies and recessive conditions from a single maternal blood draw. In the oncology space, BillionToOne offers the Northstar Select and Northstar Response liquid biopsy tests, which assist clinicians in therapy selection and real-time cancer burden monitoring for patients with advanced solid tumors. By leveraging its single-molecule next-generation sequencing (smNGS) platform, the company provides testing services directly to healthcare providers and patients.
